Program
Esflurbiprofen Topical System
Its studies are led by Teikoku Seiyaku.
Furthest: phase 1, since Jan 19, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Teikoku Seiyaku | 30 open or running | phase 1since Jan 19, 2025 | Jan 19, 2025 | none ahead |
Also a collaborator on its studies: SocraMetrics, HWI pharma services and CRM Biometrics.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2025First study: phase 1 study in HealthyFirst studyNCT06823284 · 26 enrolled · Germany
- Mar 6, 2025Phase 1 study in HealthyNCT06870422 · 28 enrolled · Germany
- Dec 15, 2025Phase 1 study in Healthy ParticipantsNCT07307794 · 90 enrolled · Germany
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07307794Healthy Participants · Germany | 1 | Completed | Mar 3, 2026 | 90 |
| NCT06870422Healthy · Germany | 1 | Completed | Apr 3, 2025 | 28 |
| NCT06823284Healthy · Germany | 1 | Completed | Feb 12, 2025 | 26 |
How it is read
Names in the registry
- “Esflurbiprofen Topical System”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.